| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Andrés Fandiño-Losada, Yabin Wei, Elin Aberg, Louise K Sjöholm, Catharina Lavebratt, Yvonne Forsel. Influence of serotonin transporter promoter variation on the effects of separation from parent/partner on depression. Journal of affective disorders. vol 144. issue 3. 2013-07-16. PMID:22884012. |
influence of serotonin transporter promoter variation on the effects of separation from parent/partner on depression. |
2013-07-16 |
2023-08-12 |
Not clear |
| Andrés Fandiño-Losada, Yabin Wei, Elin Aberg, Louise K Sjöholm, Catharina Lavebratt, Yvonne Forsel. Influence of serotonin transporter promoter variation on the effects of separation from parent/partner on depression. Journal of affective disorders. vol 144. issue 3. 2013-07-16. PMID:22884012. |
the serotonin transporter polymorphism (5-httlpr) has been reported to moderate stress sensitivity reflected for example in the relationship between childhood maltreatment and depression. |
2013-07-16 |
2023-08-12 |
Not clear |
| Hiroki Sato, Ivan Skelin, Mirko Diksi. Acute desipramine treatment reduces regional serotonin synthesis rates, while chronic treatment elevates rates, in a rat model of depression: an autoradiographic study. Neurochemistry international. vol 58. issue 7. 2013-07-12. PMID:21382427. |
acute desipramine treatment reduces regional serotonin synthesis rates, while chronic treatment elevates rates, in a rat model of depression: an autoradiographic study. |
2013-07-12 |
2023-08-12 |
rat |
| Hiroki Sato, Ivan Skelin, Mirko Diksi. Acute desipramine treatment reduces regional serotonin synthesis rates, while chronic treatment elevates rates, in a rat model of depression: an autoradiographic study. Neurochemistry international. vol 58. issue 7. 2013-07-12. PMID:21382427. |
when comparing these results to those of normal sprague-dawley rats, our results suggest that it is more informative to study 5-ht synthesis in an animal model of depression. |
2013-07-12 |
2023-08-12 |
rat |
| Melanie Stollstorff, Yuko Munakata, Arielle P C Jensen, Ryan M Guild, Harry R Smolker, Joseph M Devaney, Marie T Banic. Individual differences in emotion-cognition interactions: emotional valence interacts with serotonin transporter genotype to influence brain systems involved in emotional reactivity and cognitive control. Frontiers in human neuroscience. vol 7. 2013-07-12. PMID:23847500. |
the serotonin transporter gene (5-httlpr) influences emotional reactivity and attentional bias toward or away from emotional stimuli, and has been implicated in psychopathological states, such as depression and anxiety disorder. |
2013-07-12 |
2023-08-12 |
human |
| José Julio Rodríguez, Harun N Noristani, Alexei Verkhratsk. The serotonergic system in ageing and Alzheimer's disease. Progress in neurobiology. vol 99. issue 1. 2013-07-10. PMID:22766041. |
abnormal 5-ht neurotransmission contributes to the deterioration of cognitive processes in ageing, ad and other neuropathologies, including schizophrenia, stress, mood disorders and depression. |
2013-07-10 |
2023-08-12 |
Not clear |
| Cameron Kaplan, Yuting Zhan. Assessing the comparative-effectiveness of antidepressants commonly prescribed for depression in the US Medicare population. The journal of mental health policy and economics. vol 15. issue 4. 2013-07-09. PMID:23525835. |
patients with depression are typically treated with antidepressants - most commonly the selective serotonin reuptake inhibitors (ssris). |
2013-07-09 |
2023-08-12 |
Not clear |
| Russell E Poland, Ira M Lesser, Yu-Jui Yvonne Wan, Lev Gertsik, Jie Yao, Leslie J Raffel, Keh-Ming Lin, Hector F Myer. Response to citalopram is not associated with SLC6A4 genotype in African-Americans and Caucasians with major depression. Life sciences. vol 92. issue 20-21. 2013-07-09. PMID:23562852. |
accordingly, the purpose of this study was to determine whether ethnic variations in allele frequencies of the serotonin transporter gene-linked polymorphic region (5-httlpr) of the slc6a4 gene were related to the response to the treatment of depression. |
2013-07-09 |
2023-08-12 |
Not clear |
| Patience J Gallagher, Victor Castro, Maurizio Fava, Jeffrey B Weilburg, Shawn N Murphy, Vivian S Gainer, Susanne E Churchill, Isaac S Kohane, Dan V Iosifescu, Jordan W Smoller, Roy H Perli. Antidepressant response in patients with major depression exposed to NSAIDs: a pharmacovigilance study. The American journal of psychiatry. vol 169. issue 10. 2013-07-08. PMID:23032386. |
results nsaid exposure was associated with a greater likelihood of depression classified as treatment resistant compared with depression classified as responsive to selective serotonin reuptake inhibitors (odds ratio=1.55, 95% ci=1.21-2.00). |
2013-07-08 |
2023-08-12 |
Not clear |
| Mushtaq A Margoob, Dhuha Mushtaq, Imtiyaz Murtza, Huda Mushtaq, Arif Al. Serotonin transporter gene polymorphism and treatment response to serotonin reuptake inhibitor (escitalopram) in depression: An open pilot study. Indian journal of psychiatry. vol 50. issue 1. 2013-07-04. PMID:19771307. |
serotonin transporter gene polymorphism and treatment response to serotonin reuptake inhibitor (escitalopram) in depression: an open pilot study. |
2013-07-04 |
2023-08-12 |
Not clear |
| R Davis, A Markha. Ziprasidone. CNS drugs. vol 8. issue 2. 2013-07-04. PMID:23338220. |
it has high affinity for serotonin 5-ht(2) and dopamine d(2) receptors in vitro, with an 11-fold higher affinity for 5-ht(2) than for d(2) receptors, suggestive of a low potential for inducing motor disturbance [including extrapyramidal symptoms (eps)].▴ the effects of ziprasidone in receptor binding studies reflected its in vitro pharmacology, with more potent effects against 5-ht(2) receptor- than against d(2) receptor-mediated behaviour.▴ because ziprasidone inhibits serotonin (5-hydroxytryptamine; 5-ht) and noradrenaline (norepinephrine) reuptake, it may have anxiolytic and antidepressant effects.▴ data from phase ii and iii clinical trials have shown ziprasidone to be effective in reducing the positive and negative symptoms of, and depression associated with, schizophrenia, and in reducing anxiety in patients about to undergo dental surgery.▴ ziprasidone was generally well tolerated in phase ii and iii clinical trials, with somnolence and nausea being the most frequently reported adverse events in placebo-controlled studies. |
2013-07-04 |
2023-08-12 |
Not clear |
| Tao Jiang, Zhengxing Rong, Yiping Xu, Bing Chen, Yifan Xie, Congying Chen, Yang Lu, Yifeng Shen, Huafang Li, Jing Sun, Hongzhuan Che. Pharmacokinetics and bioavailability comparison of generic and branded citalopram 20 mg tablets: an open-label, randomized-sequence, two-period crossover study in healthy Chinese CYP2C19 extensive metabolizers. Clinical drug investigation. vol 33. issue 1. 2013-07-02. PMID:23179471. |
citalopram is a selective serotonin reuptake inhibitor (ssri) mainly prescribed to treat major depression. |
2013-07-02 |
2023-08-12 |
Not clear |
| Lynette C Daws, Wouter Koek, Nathan C Mitchel. Revisiting serotonin reuptake inhibitors and the therapeutic potential of "uptake-2" in psychiatric disorders. ACS chemical neuroscience. vol 4. issue 1. 2013-07-02. PMID:23336039. |
however, the relative lack of therapeutic efficacy of ssris has brought into question the utility of increasing extracellular serotonin for the treatment of depression. |
2013-07-02 |
2023-08-12 |
Not clear |
| Nicole L Baganz, Randy D Blakel. A dialogue between the immune system and brain, spoken in the language of serotonin. ACS chemical neuroscience. vol 4. issue 1. 2013-07-02. PMID:23336044. |
from this perspective, altered 5-ht/immune conversations are likely to contribute to risk for neurobehavioral disorders historically linked to compromised 5-ht function or ameliorated by 5-ht targeted medications, including depression and anxiety disorders, obsessive-compulsive disorder (ocd), and autism. |
2013-07-02 |
2023-08-12 |
Not clear |
| Vera Kiyasova, Patricia Bonnavion, Sophie Scotto-Lomassese, Véronique Fabre, Iman Sahly, François Tronche, Evan Deneris, Patricia Gaspar, Sebastian P Fernande. A subpopulation of serotonergic neurons that do not express the 5-HT1A autoreceptor. ACS chemical neuroscience. vol 4. issue 1. 2013-07-02. PMID:23336048. |
5-ht neurons are topographically organized in the hindbrain, and have been implicated in the etiology and treatment of psychiatric diseases such as depression and anxiety. |
2013-07-02 |
2023-08-12 |
mouse |
| Heather A Priess-Groben, Janet Shibley Hyd. 5-HTTLPR X stress in adolescent depression: moderation by MAOA and gender. Journal of abnormal child psychology. vol 41. issue 2. 2013-07-01. PMID:22836288. |
most evidence indicates that the short allele of a polymorphism in the promoter region of the serotonin transporter gene (5-httlpr) interacts with stress to influence the onset of depression. |
2013-07-01 |
2023-08-12 |
Not clear |
| T Hochstrasser, D Ehrlich, B Sperner-Unterweger, C Humpe. Antidepressants and anti-inflammatory drugs differentially reduce the release of NGF and BDNF from rat platelets. Pharmacopsychiatry. vol 46. issue 1. 2013-06-28. PMID:22699957. |
platelets store serotonin and brain-derived neurotrophic factor (bdnf) as well as amyloid precursor protein and nerve growth factor (ngf), thus platelets are of special interest in depression and alzheimer's disease, respectively. |
2013-06-28 |
2023-08-12 |
rat |
| Sinead M Gibney, Barry McGuinness, Christine Prendergast, Andrew Harkin, Thomas J Conno. Poly I:C-induced activation of the immune response is accompanied by depression and anxiety-like behaviours, kynurenine pathway activation and reduced BDNF expression. Brain, behavior, and immunity. vol 28. 2013-06-28. PMID:23201589. |
furthermore, the ability of poly i:c to deplete central tryptophan and serotonin via induction of indolamine 2,3 dioxygenase (ido), and also the ability of poly i:c to impact upon expression of the neurotrophin bdnf and its receptor trkb were examined as potential mechanisms to link inflammation to depression. |
2013-06-28 |
2023-08-12 |
rat |
| P Baldinger, G Kranz, A Höflich, M Savli, P Stein, R Lanzenberger, S Kaspe. [The effects of hormone replacement therapy on mind and brain]. Der Nervenarzt. vol 84. issue 1. 2013-06-26. PMID:22318360. |
the important role of the neurotransmitter serotonin in the pathogenesis of anxiety disorders and major depression is unquestioned, but only little is known about the influence of sex hormones on the serotonergic system. |
2013-06-26 |
2023-08-12 |
Not clear |
| Christoph Kraus, Andreas Hahn, Markus Savli, Georg S Kranz, Pia Baldinger, Anna Höflich, Christoph Spindelegger, Johanna Ungersboeck, Daniela Haeusler, Markus Mitterhauser, Christian Windischberger, Wolfgang Wadsak, Siegfried Kasper, Rupert Lanzenberge. Serotonin-1A receptor binding is positively associated with gray matter volume -- a multimodal neuroimaging study combining PET and structural MRI. NeuroImage. vol 63. issue 3. 2013-06-25. PMID:22836176. |
given the congruence of altered 5-ht(1a) receptor concentrations and gmv reduction in depression or alzheimer's disease as reported by numerous studies, these results might provide new insights towards understanding the mechanisms behind gmv alterations observed in these brain disorders. |
2013-06-25 |
2023-08-12 |
human |